Wei Hong - Hangzhou Cancer Hospital | 人才画像

基本信息

浏览量：3

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 59 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials

Xingxiang Pu,Jiawei Shou,Zemin Xiao,Jun Chen,Maoliang Xiao,Qunyi Guo, Zhongxia Ma,Wei Hong,Qianzhi Wang, Yonghui Wang,Jia Li,Chuangzhou Rao,Jie Weng,Liqin Lu,Lin Wu,Yong Fang

Advances in therapyno. 7 (2025): 3249-3264

引用0浏览0WOS引用

Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-human Phase I/Ib Study

Jinhui Xue,Yuxiang Ma,Yuanyuan Zhao,Yongsheng Wang,Wei Hong,Yan Huang,Yunpeng Yang,Wenfeng Fang,Shaodong Hong,Yang Zhang,Qianwen Liu,Yi Zhu,Hai Zhu, Sa Xiao,Li Zhang,Hongyun Zhao

Clinical cancer research an official journal of the American Association for Cancer Research (2025)

引用0浏览0WOS引用

Brain Radiotherapy Combined with Camrelizumab and Platinum-Doublet Chemotherapy for Previously Untreated Advanced Non-Small-cell Lung Cancer with Brain Metastases (C-Brain): a Multicentre, Single-Arm, Phase 2 Trial

Yanjun Xu, Kaiyan Chen,Yujin Xu,Hui Li,Zhiyu Huang,Hongyang Lu,Dingzhi Huang,Sizhe Yu,Na Han,Lei Gong,Jing Qin,Jun Chen,Fajun Xie,Wei Hong, Xiao Lin, Fengzhuo Cheng, Xiaojie Luo,Yun Fan

LANCET ONCOLOGY（2025）

引用0浏览0WOS引用

Trastuzumab Rezetecan, a HER2-directed Antibody-Drug Conjugate, in Patients with Advanced HER2-mutant Non-Small-cell Lung Cancer (Horizon-Lung): Phase 2 Results from a Multicentre, Single-Arm Study

Ziming Li,Yan Wang,Yuping Sun,Linlin Wang,Xingya Li, Longhua Sun,Zhiyi He,Haiyan Yang,Yongsheng Wang,Qiming Wang,Zhengbo Song,Wei Hong, Yong Wang,Guohao Xia,Yan Yu,Min Peng,Yong Song,Donglin Wang,Rui Meng,Jian Fang,Yongzhong Luo,Wenhua Liang,Sheng Hu, Zhihui Wang, Ke Song, You Li, Lulu Yang, Wei Shi,Shun Lu

The Lancet Oncology（2025）

引用0浏览0WOS引用

Anlotinib in Combination with Docetaxel for Advanced Nonsmall Cell Lung Cancer after Failure of Platinum-Based Treatment: A Phase 1/2 Trial

Jiawei Shou,Jun Chen,Qunyi Guo,Wei Hong, Yonghui Wang,Chuangzhou Rao,Liqin Lu,Xinmei Yang, Dan Zhu,Fen Lan,Yong Fang,Hongming Pan

Cancerno. 10 (2025): e35822-e35822

引用0浏览0WOS引用

SHR-A1811 (Antibody-Drug Conjugate) in Advanced HER2-mutant Non-Small Cell Lung Cancer: a Multicenter, Open-Label, Phase 1/2 Study

Ziming Li,Zhengbo Song,Wei Hong,Nong Yang,Yongsheng Wang,Hong Jian,Zibin Liang,Sheng Hu, Min Peng,Yan Yu,Yan Wang, Zicong Jiao,Kaijing Zhao, Ke Song, You Li, Wei Shi,Shun Lu

Signal Transduction and Targeted Therapyno. 8 (2024)

引用1浏览0WOSNATURE引用

Advances in monotherapy and combination therapy of S-1 for patients with advanced non-small cell lung cancer: a narrative review

Feiyi Cao,Cuiping Gu,Wei Hong,Ying Jin

TRANSLATIONAL CANCER RESEARCHno. 4 (2024): 2012-2025

引用0浏览0WOS引用

A Narrative Review on Advances in Neoadjuvant Immunotherapy for Esophageal Cancer: Molecular Biomarkers and Future Directions

Wenjing Wang, Lisha Ye, Huihui Li,Wei Chen,Wei Hong,Weimin Mao,Xiaoling Xu

International journal of cancer（2024）

引用1浏览0WOS引用

Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1811, an Antibody- Drug Conjugate, in Patients with Advanced HER2-mutant Non-Small Cell Lung Cancer (NSCLC): a Multicenter, Open-Label, Phase 1/2 Study

Shun Lu,Hong Jian,Wei Hong,Zhengbo Song,Nong Yang,Sheng Hu,Zibin Liang,Yongsheng Wang,Yan Wang,Min Peng,Yan Yu, You Li, Jiapeng Shuang,Kaijing Zhao

CANCER RESEARCHno. 8 (2023)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn